94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2024-12, Vol.24, p.100837, Article 100837
Main Authors: Ziogas, D., Linardou, H., Charpidou, A., Koumarianou, A., Mountzios, G., Kosmidis, P., Christodoulou, C., Mavroudis, D., Christopoulou, A.N., Korantzis, I., Baka, S., Vaslamatzis, M., Athanasiadis, I., Koutras, A., Mauri, D., Kotsakis, A., Visvikis, A., Spanoudi, F., Tsichritzis, T., Syrigos, K.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2024.100837